Neutral rating for Alimera Sciences (ALIM) confirmed by Alliance Global Partners

Alliance Global Partners confirmed its neutral recommendation for the company’s shares Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note published Tuesday, Benzinga reports.

Several other brokerages have also recently commented on ALIM. In a research report on Tuesday, Maxim Group reissued a hold rating on Alimera Sciences shares. HC Wainwright downgraded Alimera Sciences from Buy to Neutral and set a $6.00 price target for the company. in Tuesday’s research report. Finally, on Tuesday, April 30, StockNews.com downgraded Alimera Sciences from Buy to Hold.

Check out our latest stock analysis for Alimera Sciences

Alimera Sciences shares fell 0.4%

ALIM shares closed at $5.52 on Tuesday. The company has a 50-day moving average of $3.36 and a 200-day moving average of $3.65. Alimera Sciences has a fifty-two week low of $2.60 and a fifty-two week high of $5.65. The company has a debt to equity ratio of 1.71, a current ratio of 2.62 and a quick ratio of 2.51. The market capitalization of the company’s shares is $289.19 million, the P/E ratio is -3.52 and the beta coefficient is 1.15.

Alimera Sciences (NASDAQ:ALIM – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company saw ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04). Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The company’s revenue for the quarter was $23.01 million, compared to analyst estimates of $23.72 million. During the same period last year, the company reported earnings per share ($0.71). On average, sell-side analysts predict that Alimera Sciences will post earnings per share of -0.13 for the current fiscal year.

Hedge funds criticize Alimera Sciences

Hedge funds have recently added to or decreased their holdings in stocks. Fifth Lane Capital LP bought a new position in Alimera Sciences in the first quarter worth $83,000. Hillsdale Investment Management Inc. purchased a new position in shares of Alimera Sciences in the first quarter worth $169,000. Ancora Advisors LLC acquired a new stake in shares of Alimera Sciences in the first quarter worth $915,000. Worth Venture Partners LLC acquired a new stake in shares of Alimera Sciences in the third quarter worth $1,840,000. Finally, Vanguard Group Inc. increased its holdings in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Institutional investors hold 99.83% of the company’s shares.

Alimera Sciences company profile

(Get the free report)

Alimera Sciences, Inc, a pharmaceutical company, develops and markets prescription ophthalmic retinal medications. It operates in the United States, International and Operating Expense segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant used to treat diabetic macular edema (DME), a retinal disease that affects people with diabetes and can lead to severe vision loss and blindness; and to prevent recurrence of recurrent non-infectious uveitis of the posterior segment (NIU-PS).

Featured Stories

Get news and ratings for Alimera Sciences every day – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Alimera Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.